NASDAQ: COSMCosmos Health Inc Stock
$0.45-0.03 (-6.25%)
Updated Jun 13, 2025
COSM Price
$0.45
Fair Value Price
N/A
Market Cap
$12.97M
52 Week Low
$0.28
52 Week High
$1.58
P/E
-0.42x
P/B
0.5x
P/S
0.21x
PEG
N/A
Dividend Yield
N/A
Revenue
$53.55M
Earnings
-$15.13M
Gross Margin
9.4%
Operating Margin
-26.34%
Profit Margin
-39.8%
Debt to Equity
1.2
Operating Cash Flow
-$4M
Beta
0.87
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
COSM Overview
Cosmos Holdings Inc. offers branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, health care, baby products, and medical devices. It serves wholesale pharmaceutical distributors and independent retail pharmacies in the U.S., U.K., and Greece. Cosmos Holdings was incorporated in 2009 and is headquartered in Chicago, IL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine COSM's potential to beat the market
- COSM doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Distribution
Industry Rating
A
COSM
RankedUnranked of 6
RankedUnranked of 6
Be the first to know about important COSM news, forecast changes, insider trades & much more!
COSM News
Overview
Due Diligence Score
–
Industry Average (32)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how COSM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
COSM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
COSM is good value based on its book value relative to its share price (0.5x), compared to the US Medical Distribution industry average (1,382.38x)
P/B vs Industry Valuation
COSM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more COSM due diligence checks available for Premium users.
Valuation
COSM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.42x
Industry
28.76x
Market
31.36x
COSM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.5x
Industry
1,382.38x
COSM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
COSM's financial health
Profit margin
Revenue
$13.7M
Net Income
-$818.1k
Profit Margin
-6%
COSM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
COSM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$57.2M
Liabilities
$31.2M
Debt to equity
1.2
COSM's short-term assets ($27.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
COSM's short-term assets ($27.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
COSM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
COSM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$186.3k
Investing
-$7.1k
Financing
$560.9k
COSM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
COSM vs Medical Distribution Stocks
Cosmos Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.